加拿大人需要改善罕见病药物的获取，而不是更多的拒绝。

Q3 Medicine

Healthcare Papers Pub Date : 2023-04-01 DOI:10.12927/hcpap.2023.27112

Nigel S B Rawson, John Adams

{"title":"加拿大人需要改善罕见病药物的获取，而不是更多的拒绝。","authors":"Nigel S B Rawson, John Adams","doi":"10.12927/hcpap.2023.27112","DOIUrl":null,"url":null,"abstract":"Sirrs et al. (2023a) discuss what they consider \"explosive growth\" (p. 11) in the research and development (R&D) and commercialization of expensive drugs for rare diseases (DRDs). They contend that the \"status quo is no longer an option\" (Sirrs et al. 2023b: 75), so it is critical to drastically reduce the prices of DRDs and/or ration access.","PeriodicalId":35522,"journal":{"name":"Healthcare Papers","volume":"21 2","pages":"4-10"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial.\",\"authors\":\"Nigel S B Rawson, John Adams\",\"doi\":\"10.12927/hcpap.2023.27112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sirrs et al. (2023a) discuss what they consider \\\"explosive growth\\\" (p. 11) in the research and development (R&D) and commercialization of expensive drugs for rare diseases (DRDs). They contend that the \\\"status quo is no longer an option\\\" (Sirrs et al. 2023b: 75), so it is critical to drastically reduce the prices of DRDs and/or ration access.\",\"PeriodicalId\":35522,\"journal\":{\"name\":\"Healthcare Papers\",\"volume\":\"21 2\",\"pages\":\"4-10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Healthcare Papers\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12927/hcpap.2023.27112\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Healthcare Papers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12927/hcpap.2023.27112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

Sirrs等人（2023a）讨论了他们认为的罕见病昂贵药物的研发和商业化中的“爆炸性增长”（第11页）。他们认为，“现状不再是一种选择”（Sirrs等人，2023b:75），因此大幅降低DRD和/或定量供应的价格至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial.

Sirrs et al. (2023a) discuss what they consider "explosive growth" (p. 11) in the research and development (R&D) and commercialization of expensive drugs for rare diseases (DRDs). They contend that the "status quo is no longer an option" (Sirrs et al. 2023b: 75), so it is critical to drastically reduce the prices of DRDs and/or ration access.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Healthcare Papers Medicine-Health Policy

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： Integrating community-based health and social care has grabbed international attention as a way of addressing the needs of aging populations while contributing to health systems" sustainability. However, integrating initiatives in different jurisdictions work (or do not work) within very various.